Management of direct-acting antiviral agent failures

Maria Buti, Mar Riveiro-Barciela, Rafael Esteban

Research output: Contribution to journalReview articleResearchpeer-review

58 Citations (Scopus)


© 2015 European Association for the Study of the Liver. Summary Failure to respond to the approved combinations of multiple direct-acting antiviral agents is relatively low in hepatitis C virus treatment registration studies, with rates of 1% to 7%, depending on the patients' baseline characteristics. In real life, failure is slightly higher, likely because of lower compliance. Treatment failures are usually related to relapse and less often to on-treatment viral breakthrough. Hepatitis C drug-resistant variants are detected in most patients who do not achieve viral eradication. The risk of developing these variants depends on host- and virus-related factors, the properties of the drugs used, and the treatment strategies applied. Patients who carry resistance-associated variants may not obtain benefits from treatment and are at risk of disease progression and transmission of the variants. Whether hepatitis C resistance-associated variants persist depends on their type: NS3-4A variants often disappear gradually after therapy is stopped, whereas NS5A variants tend to persist for more than 2 years. The best way to prevent emergence of resistant variants is to eliminate the virus at the first treatment using highly potent antivirals with genetic barriers to resistance. In patients failing first-generation protease inhibitors, combination therapies with sofosbuvir and NS5 inhibitors have proven effective. Some salvage regimens can be shortened to 12 weeks by addition of ribavirin. The optimal treatment for patients who fail an NS5A inhibitor and those with multidrug-resistant variants remains to be defined, and research efforts should continue to focus on treatment for these patients.
Original languageEnglish
Pages (from-to)1511-1522
JournalJournal of Hepatology
Issue number6
Publication statusPublished - 1 Dec 2015


  • Daclatasvir
  • Direct-acting antivirals
  • Hepatitis C virus
  • Interferon
  • Ledipasvir
  • Resistanceassociated variants
  • Simeprevir
  • Sofosbuvir
  • Treatment


Dive into the research topics of 'Management of direct-acting antiviral agent failures'. Together they form a unique fingerprint.

Cite this